Literature DB >> 30111585

Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: A Focus on Heart Failure.

Nisha Bansal1.   

Abstract

Entities:  

Year:  2018        PMID： 30111585      PMCID： PMC6140557          DOI： 10.2215/CJN.01930218

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  In-center hemodialysis six times per week versus three times per week.

Authors:  Glenn M Chertow; Nathan W Levin; Gerald J Beck; Thomas A Depner; Paul W Eggers; Jennifer J Gassman; Irina Gorodetskaya; Tom Greene; Sam James; Brett Larive; Robert M Lindsay; Ravindra L Mehta; Brent Miller; Daniel B Ornt; Sanjay Rajagopalan; Anjay Rastogi; Michael V Rocco; Brigitte Schiller; Olga Sergeyeva; Gerald Schulman; George O Ting; Mark L Unruh; Robert A Star; Alan S Kliger
Journal:  N Engl J Med       Date:  2010-11-20       Impact factor: 91.245

2.  Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.

Authors:  Nisha Bansal; Adam Szpiro; Kristi Reynolds; David H Smith; David J Magid; Jerry H Gurwitz; Frederick Masoudi; Robert T Greenlee; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Alan S Go
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

3.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

Authors:  Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; John M Lachin; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2016-03-17       Impact factor: 91.245

5.  Outcomes Associated With Left Ventricular Assist Devices Among Recipients With and Without End-stage Renal Disease.

Authors:  Nisha Bansal; Susan M Hailpern; Ronit Katz; Yoshio N Hall; Manjula Kurella Tamura; William Kreuter; Ann M O'Hare
Journal:  JAMA Intern Med       Date:  2018-02-01       Impact factor: 21.873

6.  Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

Authors:  Ravi Thadhani; Evan Appelbaum; Yili Pritchett; Yuchiao Chang; Julia Wenger; Hector Tamez; Ishir Bhan; Rajiv Agarwal; Carmine Zoccali; Christoph Wanner; Donald Lloyd-Jones; Jorge Cannata; B Taylor Thompson; Dennis Andress; Wuyan Zhang; David Packham; Bhupinder Singh; Daniel Zehnder; Amil Shah; Ajay Pachika; Warren J Manning; Scott D Solomon
Journal:  JAMA       Date:  2012-02-15       Impact factor: 56.272

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

8.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

Authors:  Mihai Gheorghiade; Stephen J Greene; Javed Butler; Gerasimos Filippatos; Carolyn S P Lam; Aldo P Maggioni; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Elisabeth Kraigher-Krainer; Eliana T Samano; Katharina Müller; Lothar Roessig; Burkert Pieske
Journal:  JAMA       Date:  2015-12-01       Impact factor: 56.272

9.  Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.

Authors:  Burkert Pieske; Aldo P Maggioni; Carolyn S P Lam; Elisabeth Pieske-Kraigher; Gerasimos Filippatos; Javed Butler; Piotr Ponikowski; Sanjiv J Shah; Scott D Solomon; Andrea-Viviana Scalise; Katharina Mueller; Lothar Roessig; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

10.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Authors:  Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad
Journal:  Eur Heart J       Date:  2013-05-27       Impact factor: 29.983
  10 in total
  1 in total

1.  The ABCs in the Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: An Introductory Remark on Expert Perspectives.

Authors:  Christoph Wanner
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-15       Impact factor: 8.237
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.